Acute Myeloblastic Leukemia With Maturation - 179 Studies Found
Terminated |
: Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia :
|
Completed |
: Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia :
|
Recruiting |
: Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia :
: |
Recruiting |
: CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML :
|
Active, not recruiting |
: Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy :
|
Completed |
: High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma :
|
Terminated |
: Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia :
|
Completed |
: Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia :
|
Active, not recruiting |
: MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia :
|
Active, not recruiting |
: Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia :
: |